U.S. Outcomes with Transcatheter Mitral Repair

Registry data on the commercial MitraClip device demonstrate good acute safety and efficacy.

The MitraClip system for transcatheter mitral repair of severe mitral regurgitation (MR) was approved in the U.S. in October 2013. These investigators used data in the U.S. Transcatheter Valve Therapy (TVT) Registry from the Society of Thoracic Surgeons (STS) and American College of Cardiology to study acute outcomes in 2952 patients (median age, 82; 56% men) treated at 145 hospitals until September 2015 and 1-year outcomes in 1867 patients with Medicare linkage data.

All patients had comorbidities, including frailty in 50%, resulting in an STS predicted risk of 30-day mortality for mitral valve replacement of 9.2% (interquartile range, 6%–14%). Degenerative (primary) MR was present in 86% of patients. MR was graded as 3 or 4 in 93%.

In-hospi…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)